StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $1.99 | $1.98 | -0.50% | 0.3M |
| 05-13 | $1.95 | $1.92 | -1.54% | 0.0M |
| 05-14 | $1.92 | $1.92 | +0.00% | 0.0M |
| 05-15 | $1.93 | $1.89 | -2.07% | 0.0M |
| 05-18 | $1.87 | $1.89 | +1.07% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 |
|---|---|---|---|---|
Revenue | $2.35M | $1.11M | $8.01M | $6.20M |
Operating Income | $-4.97M | $-199.00K | $-1.01M | $-750.33K |
Net Income | $-1.16M | $-293.97K | $-1.45M | $-1.14M |
EPS (Diluted) | $-1.85 | $-761.59 | $-6001.39 | $-2955.71 |
Total Assets | $9.03M | $1.44M | $1.38M | $1.28M |
Total Liabilities | $3.20M | $5.25M | $5.77M | $4.13M |
Cash & Equivalents | $4.12M | $2.52M | $101.90K | $743.00K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 2.62M | 133.08K | 0 | 704.70K |